MP63-11 ADVANCED AGE (>70 YEARS) DOES NOT AFFECT ONCOLOGICAL OUTCOMES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH ADEQUATE BACILLUS CALMETTE-GUERIN: A COMPETING RISK ANALYSIS FROM a TERTIARY CARE CENTER.

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP63-11 ADVANCED AGE (>70 YEARS) DOES NOT AFFECT ONCOLOGICAL OUTCOMES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH ADEQUATE BACILLUS CALMETTE-GUERIN: A COMPETING RISK ANALYSIS FROM a TERTIARY CARE CENTER. Roberto Contieri, Valentina Grajales, Wei Shen Tan, Kelly Bree, Patrick Hensley, Charles C. Guo, Graciela M. Nogueras-Gonzalez, Neema Navai, Colin P. Dinney, and Ashish M. Kamat Roberto ContieriRoberto Contieri More articles by this author , Valentina GrajalesValentina Grajales More articles by this author , Wei Shen TanWei Shen Tan More articles by this author , Kelly BreeKelly Bree More articles by this author , Patrick HensleyPatrick Hensley More articles by this author , Charles C. GuoCharles C. Guo More articles by this author , Graciela M. Nogueras-GonzalezGraciela M. Nogueras-Gonzalez More articles by this author , Neema NavaiNeema Navai More articles by this author , Colin P. DinneyColin P. Dinney More articles by this author , and Ashish M. KamatAshish M. Kamat More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003321.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: According to the newly released European Association of Urology (EAU) prognostic factor risk groups, age over 70 should be considered an additional clinical risk factor for progression amongst patients with non-muscle invasive bladder cancer (NMIBC). However, this statement is based on an analysis of patients who did not receive intravesical BCG therapy. Herein, we aim to evaluate the impact of age on oncological outcomes in NMIBC patients treated with adequate BCG. METHODS: We performed an IRB approved retrospective study analyzing patients with NMIBC treated with adequate BCG at our institution from 2000 to 2020. Based on EAU guidelines, patients were stratified into two groups according to age ( <70 yrs and>70 yrs). Primary endpoint was cancer-specific mortality (CSM). The cumulative incidence method was used to estimate the risk of CSM, high-grade (HG) recurrence and progression to muscle-invasive BC or metastatic disease after accounting for other causes of death (OCD) as a competing risk event; curves were compared with the Pepe-Mori test. Multivariate competing-risks regression analyses were used to predict HG recurrence and progression according to age after accounting for OCD. RESULTS: A total of 632 patients treated with adequate BCG were identified (355 <70 yrs versus 277>70 yrs). The median follow-up was 64.6 months (Interquartile range: 35.3–99.4) . Older patients were more likely to have a concomitant CIS (29.0% vs. 35.7%, p=0.072), and less likely to undergo second resection (reTUR) (66.2% vs. 56.5%, p=0.013). Despite this, at multivariate competing-risk regression analyses, age>70 did not emerge as an independent predictor of HG recurrence or progression (SHR 1.07, 95% CI: 0.78–1.46; p=0.687 and SHR: 1.60; 95% CI: 0.89–2.89; p=0.118). OS at 5 (94.2% vs. 78.5%) and 10 years (81.1% vs 42.3%) was considerably lower in the>70 yrs group. However, the 5-yr CSM overlap between the age groups (5.1% 95% CI: 2.7-8.7 vs. 2.0% 95% CI: 0.8–4.2). CONCLUSIONS: Age >70 was not associated with significantly worse oncological outcomes in NMIBC patients treated with adequate BCG Source of Funding: This research was supported by the Wayne B. Duddlesten Professorship in Cancer Research, the Raymond and Maria Floyd Bladder Cancer Research Foundation Grant, NIH/NCI UTMD Anderson SPORE in Genitourinary Cancer (p50CA091846), the Cancer Center Support Grant (NCI Grant P30 CA016672). © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e875 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Roberto Contieri More articles by this author Valentina Grajales More articles by this author Wei Shen Tan More articles by this author Kelly Bree More articles by this author Patrick Hensley More articles by this author Charles C. Guo More articles by this author Graciela M. Nogueras-Gonzalez More articles by this author Neema Navai More articles by this author Colin P. Dinney More articles by this author Ashish M. Kamat More articles by this author Expand All Advertisement PDF downloadLoading ...